Tissue Regenix Group PLC Pan European distribution agreement with Arthrex (1208H)
November 13 2018 - 2:01AM
UK Regulatory
TIDMTRX
RNS Number : 1208H
Tissue Regenix Group PLC
13 November 2018
Tissue Regenix Group plc
Pan European distribution agreement with Arthrex, Inc.
Leeds, 13 November 2018 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company today announces that its subsidiary 'CellRight
Technologies', has entered into an agreement, effective
immediately, allowing Arthrex, Inc. to distribute its proprietary
'BioRinse' bone portfolio throughout Europe, with the initial focus
on the UK.
This new agreement builds on the existing US relationship signed
in March 2018 and is a direct result of the collaborative work that
Arthrex and Tissue Regenix have been undertaking to evaluate
additional business opportunities.
Steve Couldwell, CEO, Tissue Regenix Group plc commented: "I am
delighted to announce an extension to our collaboration with
Arthrex. Since signing the US distribution agreement in March we
have continued to build a strong alliance, identifying areas where
we can work together and leverage the expertise of both companies.
This European agreement allows us to exploit not only our ability
to import our BioRinse bone portfolio into the UK facility, but
also Arthrex' expansive distribution network, another significant
milestone towards our vision of building a leading force in
regenerative medicine."
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073 / 07920 272
Caitlin Pearson, Head of Communications 441
----------------------------------------- -------------------------------
Jefferies International Ltd Tel: 0207 029 8000
Simon Hardy / Christopher Binks
----------------------------------------- -------------------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Mo Noonan/ Mary Whittow
========================================= ===============================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTGGGMCGUPRPGP
(END) Dow Jones Newswires
November 13, 2018 02:01 ET (07:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024